News

Ovation LIMS/LIS enables prominent molecular diagnostic laboratories to provide comprehensive test results to thousands of clinicians nationwide. Now, these labs can deliver the Arkstone OneChoice report combined with the patient’s detected pathogens and antibiotic resistance genes outlined in the infectious disease laboratory results.

MedsMatrix expands on OneChoice by giving the provider a clear understanding of what different treatment options are, and even some insight into how the OneChoice decision engine came to its conclusions

Dr. Juan Carlos Gómez de la Torre Pretell, founder of the Peruvian Institute of Molecular Biology, will be an integral part of Arkstone’s advancements in the use of artificial intelligence to democratize infectious disease expertise and increase antibiotic stewardship.

The Antimicrobial Stewardship Monthly Report includes month-to-month tracking of infections from many different sources, including respiratory, wound, urine, and GI. The report breaks down the most common types of infections and resistance genes and analyzes this data so that trends are easily visible, allowing for the implementation of proactive surveillance and infection control policies.

The improved ArkScore interprets the complex results of a molecular diagnostic test and presents an optimal course of treatment. This simplification allows each physician to quickly understand how treatment options are affected by the patient’s profile, presence of specific organisms, and resistance genes.

Arkstone Medical Solutions has filed Provisional U.S. Patent Applications covering technologies that aid physicians in making educated and informed decisions for patient care. These systems are already in use on the renowned Arkstone Report, which analyzes molecular diagnostic lab results and guides physicians with pinpoint interpretations and recommendations.

Arkstone's OneChoice technology automatically analyzes many factors like specimen source, organisms and genes detected, patient age and gender, and diagnosis, to arrive at a targeted precision-guided treatment recommendation. By incorporating which antibiotics the patient may be allergic to, the recommendations are now even more tailored to the specific patient's needs.

The new COVID-19 Pandemic Alert section incorporates infection statistic information from Johns Hopkins University, specific to the location of the patient, to help keep providers informed of potential increases in infection rates. While no treatment or vaccine is yet available, the Arkstone Report continues to assist providers in making informed care decisions by including the latest treatment information at the time of the lab test.